Healthcare
FDA Approves Palbociclib for Advanced Breast Cancer
The US Food and Drug Administration has approved palbociclib for advanced HR+/HER2+ breast cancer following positive results from the Patina trial.
The US Food and Drug Administration has approved palbociclib for advanced HR+/HER2+ breast cancer following positive results from the Patina trial.